AKT1 and cancer: As a valuable therapeutic target in cancer and other pathologies, ANXA7 appears to be a rapamycin-like endogenous regulator that can balance cell growth and survival in homeostasis and tumorigenesis instead of delivering a potentially detrimental “chemical knockout” of the mTOR/Akt/PI3K pathway components.